NCT05494697Phase 2Suspended

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Study sponsor: AIM ImmunoTech Inc. · AIM

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2031-02Estimated

Enrollment · participants90Estimated

Source updated2026-08-19Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-19 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2029-12

+ Updated value

2031-02

Check registry source

Posted 2025-10-14 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2028-09

+ Updated value

2029-12

Check registry source

Study details

Conditions studied

Pancreatic Cancer

Treatments or interventions studied

RintatolimodDrugAlso known as Ampligen, poly I : poly C12U

Primary outcomes · main study measures

measure: Progression Free Survival (PFS); description: PFS is defined as the time, in months, from date of randomization to date of the first documentation of definitive disease progression as per RECIST v1.1 and iRECIST (the initial progressive disease (PD)) or death due to any cause.; timeFrame: Randomization until disease progression, death, or end of study up to 182 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history